Erasca
San Diego, US · 3 known investors
Erasca is a clinical-stage oncology company developing therapies targeting RAS- and MAPK pathway-driven cancers using a modality-agnostic approach including small molecules, large molecules, and protein degraders.
BiotechDeep TechDigital HealthMedical Devices
Investors · 3
In the news
- The Bull Case For Erasca (ERAS) Could Change Following ERAS-0015 IP Dispute And Fundraising Moves - Simply Wall St Newssimplywall.st · 2026
- ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuitprnewswire.com · 2026
- Kaplan Fox Notifies Erasca, Inc. (ERAS) Investors of a Securities Class Action Deadline on August 10, 2026newsfilecorp.com · 2026
- Erasca: A Credible Rival To Revolution's Daroxonrasib, At A Cheaper Price Point (ERAS) | Seeking Alphaseekingalpha.com · 2026
- Erasca Raises $550M for RAS-Targeting Cancer Pipelineallsci.com · 2026
- Erasca (Nasdaq: ERAS) raises $516M net in July stock salestocktitan.net · 2026